2-(2,6-Dioxopiperidin-3-yl)-5-hydrazinylisoindoline-1,3-dione
98%
- Product Code: 167492
CAS:
497146-95-9
| Molecular Weight: | 288.26 g./mol | Molecular Formula: | C₁₃H₁₂N₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, light-proof, inert gas |
Product Description:
Used primarily in pharmaceutical research, this compound serves as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its hydrazine functionality allows for further chemical modifications, enabling the development of novel PROTACs (proteolysis-targeting chimeras) and other bifunctional molecules designed to degrade disease-causing proteins. It is also explored for its potential in oncology and immunomodulatory therapies due to its structural similarity to thalidomide derivatives. Commonly employed in medicinal chemistry for linker construction in conjugation strategies, it supports the creation of highly specific drug candidates with improved pharmacokinetic profiles.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 50mg | 10-20 days | ฿9,700.00 |
+
-
|
| 250mg | 10-20 days | ฿28,020.00 |
+
-
|
| 100mg | 10-20 days | ฿16,480.00 |
+
-
|
2-(2,6-Dioxopiperidin-3-yl)-5-hydrazinylisoindoline-1,3-dione
Used primarily in pharmaceutical research, this compound serves as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its hydrazine functionality allows for further chemical modifications, enabling the development of novel PROTACs (proteolysis-targeting chimeras) and other bifunctional molecules designed to degrade disease-causing proteins. It is also explored for its potential in oncology and immunomodulatory therapies due to its structural similarity to thalidomide derivatives. Commonly employed in medicinal chemistry for linker construction in conjugation strategies, it supports the creation of highly specific drug candidates with improved pharmacokinetic profiles.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :